Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to...

Full description

Bibliographic Details
Main Authors: A. A. Kubanov, A. L. Bakulev, M. I. Gluzmin, M. M. Kokhan, L. S. Kruglova, N. S. Rudneva, O. Yu. Olisova, E. V. Sokolovsky, M. M. Khobeish
Format: Article
Language:Russian
Published: State Scientific Center of Dermatovenereology and Cosmetology 2019-12-01
Series:Vestnik Dermatologii i Venerologii
Subjects:
plaque psoriasis
psoriatic arthritis
genetically engineered biological drugs
tnf-α inhibitors
certolizumab pegol
Online Access:https://www.vestnikdv.ru/jour/article/view/524

Internet

https://www.vestnikdv.ru/jour/article/view/524

Similar Items